Moderna Settles COVID-19 Vaccine Patent Dispute

Moderna has settled a long-running legal dispute over the lipid nanoparticle technology used in its COVID-19 vaccine. The settlement involves a payment of up to $2.25 billion to Roivant Sciences===Genevant Sciences, a subsidiary of Roivant Sciences, and Arbutus Biopharma. Moderna will pay $950 million upfront in July 2026, with an additional $1.3 billion contingent on a separate legal appeal. A key aspect of the agreement is that Moderna will not owe royalties for the technology in its future vaccines. This resolution is seen as a significant win for Moderna, as it removes a major legal uncertainty and allows the company to shift investor focus back to its developing cancer vaccines. Analysts noted that the payment is less than the $3 billion Wall Street had feared. However, concerns remain about Moderna's cash reserves if the full contingent payment becomes necessary, and the timing and scale of its ongoing lawsuit against Pfizer and BioNTech.